T0	Participants 60 92	anti-herpes virus therapy in MS.
T1	Participants 204 253	patients with relapsing-remitting MS in a phase 2
T2	Participants 443 559	Patients were eligible for the study if they had had two or more MS relapses in the 2-year period before enrollment.
T3	Participants 560 633	Seventy patients with Expanded Disability Status Scale scores of 0 to 5.5
T4	Participants 1892 1992	patients with relapsing-remitting MS who had two or more relapses during the previous 2-year period.
T5	Participants 2397 2462	patients with MS and high levels of MRI-evident disease activity.